Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Net income
Kiniksa Pharmaceuticals International (KNSA) net income by quarter
Kiniksa Pharmaceuticals International's net income was $47.3M in Q3 2026 (third quarter 2026), +86% from Q2 2026. Over the last 7 quarters it ranged from $8.5M (Q1 2025) to $47.3M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $47.3M | +86% | +157% |
| Q2 2026 | $25.4M | +13% | +43% |
| Q1 2026 | $22.6M | +59% | +165% |
| Q4 2025 | $14.2M | -23% | — |
| Q3 2025 | $18.4M | +3% | — |
| Q2 2025 | $17.8M | +109% | — |
| Q1 2025 | $8.5M | — | — |
Q3 2026 at a glance
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kiniksa Pharmaceuticals International's net income?
Kiniksa Pharmaceuticals International's net income was $47.3M in Q3 2026 (third quarter 2026), +86% from Q2 2026.
How has Kiniksa Pharmaceuticals International's net income changed?
Over the last 7 quarters it ranged from $8.5M (Q1 2025) to $47.3M (Q3 2026).
Q3 2026 results → · How Kiniksa Pharmaceuticals International makes money →